The FDA has approved Prograf (tacrolimus, from Astellas) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients. This approval was based ...
A new granule formulation of Prograf (tacrolimus; Astellas) has been made available for the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplant, and ...
Two drugs have been recalled because their capsules might be empty — and the consequences could be deadly. Astellas Pharma’s Prograf gets prescribed after heart, liver, kidney or lung transplants.
NORTHBROOK, Ill., July 20, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced that the U.S. Food and Drug Administration (FDA) has ...
Bottles of two medications that prevent the body's rejection of transplanted organs were recalled because the capsules may be empty. Astellas Pharma US, Inc. announced this week it is voluntarily ...
Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients DEERFIELD, Ill., May 28 /PRNewswire/ -- The Food and ...
Astellas Pharma has been boosted by the news that regulators in Japan have granted an additional approval for the firm’s blockbuster immunosuppressant Prograf. Astellas Pharma has been boosted by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback